Sensitizers related to RNA modification are also widely studied, such as the target of m6A methylation of RNA; the METTL3-METTL14 heterodimer is involved in the biological behavior of malignant bone marrow cells and glioblastoma, breast cancer, hepatocellular carcinoma, leukemia, etc. The expression levels of demethylase FTO and methylase (METTL3 and WTAP) are positively correlated with cancer cell resistance to chemotherapy and radiotherapy, and the downregulation of these genes can increase the radiosensitivity of glioma, pancreatic cancer and colon cancer [159]. Here, METTL3 is linked to central nervous system cancer.